Paul Tappenden

Paul Tappenden publication distribution in Economics and Finance in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Economics and Finance in 2026. The highlighted bar marks where Paul Tappenden sits on this spectrum.

Paul Tappenden D-index placement in Economics and Finance in 2026

The chart shows the D-index (discipline H-index) distribution of Economics and Finance scientists ranked by Research.com in 2026. The highlighted bar marks where Paul Tappenden sits on this spectrum.

Best Publications

• Chemoprevention of colorectal cancer: systematic review and economic evaluation

  K Cooper;H Squires;C Carroll;D Papaioannou

  296
  Citations

• A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative

  J Chilcott;M Lloyd Jones;J Wight;K Forman

  283
  Citations

• A systematic review and economic evaluation of exercise referral schemes in primary care: a short report.

  Fiona Campbell;Mike Holmes;Emma Everson-Hock;Sarah Davis

  245
  Citations

• A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models.

  RG Richards;FC Sampson;Stephen Beard;P Tappenden

  221
  Citations

• Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis

  Jim Chilcott;Chris Mccabe;Paul Tappenden;Anthony O'hagan

  195
  Citations

• Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

  P Tappenden;R Jones;S Paisley;C Carroll

  192
  Citations

• Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation

  Paul Tappenden;R. Jackson;K. Cooper;A. Rees

  180
  Citations

• A review and critique of modelling in prioritising and designing screening programmes.

  J. Karnon;E. Goyder;P. Tappenden;S. McPhie

  178
  Citations

• Option appraisal of population-based colorectal cancer screening programmes in England

  Paul Tappenden;James Bromley Chilcott;Simon Eggington;Julietta Patnick

  171
  Citations

• The Clinical Effectiveness and Cost-Effectiveness of Home-Based, Nurse-Led Health Promotion for Older People: A Systematic Review

  P Tappenden;F Campbell;A Rawdin;R Wong

  159
  Citations

• Distributional cost-effectiveness analysis of health care programmes--a methodological case study of the UK Bowel Cancer Screening Programme.

  Miqdad Asaria;Susan Griffin;Richard Cookson;Sophie Whyte

  148
  Citations

• The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation

  D Hind;P Tappenden;I Tumur;S Eggington

  142
  Citations

• Methodological issues in the economic analysis of cancer treatments.

  Paul Tappenden;Jim Chilcott;Sue Ward;Simon Eggington

  133
  Citations

• The role of modelling in prioritising and planning clinical trials.

  Jim Chilcott;Alan Brennan;Andrew Booth;Jonathan Karnon

  130
  Citations

• Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis

  P Tappenden;J B Chilcott;S Eggington;J Oakley

  127
  Citations

• The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales

  P. Tappenden;R. Jones;S. Paisley;C. Carroll

  113
  Citations

• Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy

  Linda Sharp;Lesley Tilson;Sophie Whyte;Alan O'Ceilleachair

  109
  Citations

• The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No. 150 and part review of technology appraisal No. 118): a systematic review and economic model

  Martin Hoyle;Louise Crathorne;Jaime Peters;Tracey Jones-Hughes

  106
  Citations

• Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review

  J Chilcott;P Tappenden;A Rawdin;M Johnson

  104
  Citations

• The Multiple Sclerosis Risk Sharing Scheme Monitoring Study – early results and lessons for the future

  Mark Pickin;Cindy L Cooper;Timothy Chater;Anthony O'Hagan

  93
  Citations